氯胍增强索托拉西布抑制KRAS<sup>G12C</sup>野生型膀胱癌细胞增殖和迁移的作用机制

Abstract
Figure/Table
References
Related Citation (11)

Download: PDF (2698 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore whether proguanil can enhance the sensitivity of KRAS^G12C wild-type bladder cancer cells to sotorasib and its mechanism. Methods MTT, clone formation assay and Compusyn software were used to test whether the combination of sotorasib and proguanil can enhance the inhibition of KRAS^G12C wild-type bladder cancer cell proliferation and how the combined effect is. Scratch experiment was used to detect the inhibitory effect on cell migration, and finally, WB experiment was used to detect the inhibitory effect on proliferation related proteins. Results Sotorasib combined with proguanil enhanced the inhibition of proliferation and migration of KRAS^G12C wild-type bladder cancer cells. And the inhibitory effect on the expression of proliferation related proteins such as p-cRAF and p-ERK was enhanced. Conclusion Proguanil can enhance the sensitivity of KRAS^G12C wild-type bladder cancer cells to sotorasib by inhibiting RAF/ERK pathway.

Key words： wild-type bladder cancer cells KRAS^G12C proguanil sotorasib proliferation migration mechanism

Received: 28 October 2023

PACS:	R363
	R96

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Zhirong
	WANG Weifan
	XIAO Di
	YANG Xiaoping

Cite this article:

ZHANG Zhirong,WANG Weifan,XIAO Di等. Mechanism of Proguanil Enhancing the Inhibitory Effect of Sotorasib on Proliferation and Migration of KRAS^G12C Wild-type Bladder Cancer Cells[J]. HuNan ShiFan DaXue XueBao(YiXueBan), 2023, 20(6): 9-13.

URL:

http://yxb.hunnu.edu.cn/EN/ OR http://yxb.hunnu.edu.cn/EN/Y2023/V20/I6/9

[1] DOBRUCH J, OSZCZUDŁOWSKI M. Bladder Cancer: Current Challenges and Future Directions[J]. Medicina (Kaunas, Lithuania), 2021, 57(8): 749.
[2] MARTINEZ RODRIGUEZ R H, BUISAN RUEDA O, IBARZ L. Bladder cancer: Present and future[J]. Medicina clinica, 2017, 149(10): 449-455.
[3] SHINOHARA N, KOYANAGI T.Ras signal transduction in carcinogenesis and progression of bladder cancer: molecular target for treatment?[J]. Urological research, 2002, 30(5): 273-281.
[4] MOORE A R, ROSENBERG S C, MCCORMICK F, et al.RAS-targeted therapies: is the undruggable drugged?[J]. Nature reviews Drug discovery, 2020, 19(8): 533-552.
[5] SKOULIDIS F, LI B T, DY G K, et al.Sotorasib for Lung Cancers with KRAS p. G12C Mutation[J]. N Engl J Med, 2021, 384(25): 2371-2781.
[6] NAKAJIMA E C, DREZNER N, LI X, et al.FDA Approval Summary: Sotorasib for KRAS G12C-Mutated Metastatic NSCLC[J]. Clin Cancer Res, 2022, 28(8): 1482-1486.
[7] HONG D S, FAKIH M G, STRICKLER J H, et al.KRAS (G12C) Inhibition with Sotorasib in Advanced Solid Tumors[J]. N Engl J Med, 2020, 383(13): 1207-1217.
[8] BLAIR H A.Sotorasib: First Approval[J]. Drugs, 2021, 81(13): 1573-9.
[9] JANES M R, ZHANG J, LI L S, et al. Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor [J]. Cell, 2018, 172(3): 578-589. e17.
[10] MCKEAGE K, SCOTT L.Atovaquone/proguanil: a review of its use for the prophylaxis of Plasmodium falciparum malaria[J]. Drugs, 2003, 63(6): 597-623.
[11] DENG J, PENG M, ZHOU S, et al.Metformin targets Clusterin to control lipogenesis and inhibit the growth of bladder cancer cells through SREBP-1c/FASN axis[J]. Signal Transduct Target Ther, 2021, 6(1): 98.
[12] XIAO D, HU X, PENG M, et al.Inhibitory role of proguanil on the growth of bladder cancer via enhancing EGFR degradation and inhibiting its downstream signaling pathway to induce autophagy[J]. Cell Death Dis, 2022, 13(5): 499.
[13] AWAD M M, LIU S, RYBKIN, II, et al.Acquired Resistance to KRAS (G12C) Inhibition in Cancer[J]. N Engl J Med, 2021, 384(25): 2382-2393.
[14] XU S, CAO Y, LUO Y, et al.Synthesis, Anti-Proliferative Evaluation and Mechanism of 4-Trifluoro Methoxy Proguanil Derivatives with Various Carbon Chain Length[J]. Molecules (Basel, Switzerland), 2021, 26(19): 5775.
[15] XIAO D, LU Z, WANG Z, et al.Synthesis, biological evaluation and anti-proliferative mechanism of fluorine-containing proguanil derivatives[J]. Bioorg Med Chem, 2020, 28(2): 115258.
[16] CANON J, REX K, SAIKI A Y, et al.The clinical KRAS (G12C) inhibitor AMG 510 drives anti-tumour immunity[J]. Nature, 2019, 575(7781): 217-323.
[17] KOGA T, SUDA K, FUJINO T, et al.KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments[J]. J thorac Oncol, 2021, 16(8): 1321-1332.
[18] LIU J, KANG R, TANG D.The KRAS-G12C inhibitor: activity and resistance[J]. Cancer gene therapy, 2022, 29(7): 875-878.
[19] RYAN M B, FECE DE LA CRUZ F, PHAT S, et al. Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRAS (G12C) Inhibition[J]. Clin Cancer Res, 2020, 26(7): 1633-1643.
[20] DUNNETT-KANE V, NICOLA P, BLACKHALL F, et al.Mechanisms of Resistance to KRAS (G12C) Inhibitors[J]. Cancers, 2021, 13(1): 151.
[21] MISALE S, FATHERREE J P, CORTEZ E, et al.KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition[J]. Clin Cancer Res, 2019, 25(2): 796-807.
[22] ZHANG N, SUNDQUIST J, SUNDQUIST K, et al.Proguanil and atovaquone use is associated with lower colorectal cancer risk: a nationwide cohort study[J]. BMC medicine, 2022, 20(1): 439.